The expression and coexpression of BCL6 negative, P53 positive and BCL2S + have certain value in the prognostic evaluation of DLBCL, especially in the group of age≤60-year-old and IPI score 0–2. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.